Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2LEBV + 2LXFS
- Development stage
- Unknown
- Lead developer
- Labo'Life España
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Sublingual
01
Overview
2LEBV + 2LXFS is a combination micro-immunotherapy regimen developed by Labo'Life for the treatment of Epstein-Barr Virus (EBV) infections and associated asthenia (fatigue). Micro-immunotherapy is a therapeutic approach that utilizes low doses of immune mediators, such as cytokines and specific nucleic acids (DNA and RNA), to modulate the host's immune response. 2LEBV is specifically formulated to target EBV by incorporating specific nucleic acids (SNA-EBV) and immune mediators like Interleukin-2 (IL-2) and Interferon-alpha (IFN-alpha). 2LXFS is typically used as a supportive component to address fatigue and support the immune system's overall function. The treatment is administered orally, with the contents of capsules taken sequentially (numbered 1 through 10) to mimic the natural physiological immune response over a 6-month period.
- Brand names
- 2LEBV + 2LXFS
- Other names
- Micro-immunotherapy 2LEBVMicro-immunotherapy2LEBVMicro-immunotherapy-2LEBVMicro-immunotherapy 2LXFSMicro-immunotherapy2LXFSMicro-immunotherapy-2LXFS
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)IL1R1 (Interleukin-1 Receptor Type 1)HLA-DR (Human leukocyte antigen DR)DNA
Beyond the preview
Go deeper on 2LEBV + 2LXFS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2LEBV + 2LXFS.